Plain-English translation of NCT07343986 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new combination approach for newly diagnosed glioblastoma using EGFR BATs—immune cells that are taken from your own body, modified in the lab to recognize and fight your cancer, and then given back to you as infusions. The researchers are pairing these immune cell infusions with a procedure called low-intensity focused ultrasound, which uses sound waves to temporarily open the barrier that surrounds the brain, potentially allowing the immune cells to reach the tumor more effectively.
The blood-brain barrier is a natural protective layer around the brain that keeps most immune cells out—which means this treatment can't reach tumors as easily. This trial is exploring whether opening that barrier with ultrasound can help the new immunotherapy work better against brain cancer.
You likely qualify if…
You likely don't qualify if…
You will receive a series of infusions of the engineered immune cells over time. Depending on which study group you're assigned to, you'll also receive focused ultrasound procedures at different timepoints to help open the blood-brain barrier. The researchers will track the cells using imaging scans to see where they travel in your body. Throughout the study, you'll have regular blood tests and imaging scans to monitor your safety and how well the treatment is working.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
United States